Daniel W Sherbenou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8623760/publications.pdf

Version: 2024-02-01

1937457 1872570 11 143 4 6 citations h-index g-index papers 11 11 11 310 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations. Journal of Clinical and Translational Science, 2022, 6, 54-54.	0.3	O
2	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clinical Cancer Research, 2021, 27, 819-830.	3.2	6
3	A case for improving frail patient outcomes in multiple myeloma with phenotypeâ€driven personalized medicine. Aging and Cancer, 2021, 2, 6-12.	0.5	O
4	Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers, 2021, 13, 1686.	1.7	25
5	Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia. Blood, 2021, 138, 630-630.	0.6	O
6	Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients. Blood, 2020, 136, 37-38.	0.6	4
7	Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma. Blood, 2020, 136, 12-13.	0.6	O
8	Disruption of IRE1 \hat{l} ± through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16420-16429.	3.3	78
9	Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples. Blood, 2019, 134, 4404-4404.	0.6	O
10	A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients. Blood, 2018, 132, 3203-3203.	0.6	1
11	Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 545-554.	0.2	29